Alcon reported third quarter 2026 revenue of $2.72 billion, slightly missing analyst estimates of $2.73 billion, while core diluted EPS of $0.91 exceeded the expected $0.89. Performance was bolstered by a 6% increase in Vision Care and 11% growth in surgical equipment, though the premium lens segment faced headwinds. The company tightened its full-year 2026 guidance, now projecting constant-currency sales growth of approximately 6%.
Key Highlights
- Core operating margin expanded 160 basis points to 21.8%, driven by manufacturing efficiencies and a $58 million U.S. government tariff refund.
- Surgical equipment sales surged 11% on a constant-currency basis, led by the ongoing launch momentum of the Unity platform.
- Vision Care growth of 6% was supported by price increases and a favorable product mix in premium contact lenses and ocular health products.